Biotech
Azimutus Biotech Advisory
Oxford-based biotech and healthcare advisory practice
Based in Oxford, with strong links with the Oxford-Cambridge-London golden triangle, our senior advisory team has extensive Biotech, Healthcare and Big Pharma experience and close ties to the European and US venture capital ecosystem. Operating since 2020.
Selected experience in the healthcare/biotech sector
PHARMACEUTICAL COMPANY
The Americas/Poland
Ongoing project
BIOTECHNOLOGY COMPANY
Europe
Ongoing project
MTZ CLINICAL RESEARCH
Clinical Research Organization
Warsaw
January 2021
NEURO DEVICE GROUP
Electroceuticals
United States
2021
SDS OPTIC
Cancer diagnostics
Poland
2021
Selected Team members (Biotech-focused)
Our team has vast experience in both biotech/pharma dealmaking and drug discovery
WITEK HRUZEWICZ
- Founding Partner at M&A advisory firm Azimutus
- 25+ years of professional experience, 18 in investment banking encompassing corporate finance, M&A, venture capital and high tech start-ups
- Before founding Azimutus, he worked at McKinsey & Company
- Prior to that, he worked in the biotech industry in Silicon Valley, at Celera Corporation and Theravance Biopharma
- MBA from Columbia Business School (New York) and IESE (Barcelona); graduate degree from UC Berkeley (Medicinal Chemistry), undergraduate degree from Boston University (chemistry)
PROF. PAUL BRENNAN
- Professor of Medicinal Chemistry and head of chemistry of the Alzheimer’s Research UK Oxford Drug Discovery Institute in the Centre for Medicines Discovery at the University of Oxford
- Worked for Amgen developing kinase inhibitors for oncology and at Pfizer as medicinal chemistry design lead
- Post-doctoral fellowship at University of Cambridge, PhD from UC Berkeley (Medicinal Chemistry), undergraduate degree from UC Davis
…with presence in both the UK and USA (six team members based in the UK)
How does Azimutus bring value to biotech companies?
Mix of Oxford-based industry experience and pan-European transaction experience
M&A
(Post-VC stage)
incl. in-out licensing
- Access to and relationship with Big Pharma Companies
- Transaction experience spanning over 100 executed processes
Capital raising
(private equity,
venture capital)
- Access to US-based PE funds
- Access to European and American life sciences venture capital
Investments
- Providing seed and Series A funding to biotech companies